Overcoming therapeutic failure in osteosarcoma<i>via</i>Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles

Li, Xiangyu; Wang, Liying; Wang, Li; Yu, J.; Lu, Guohao; Zhao, Wei; Miao, Congxiu; Zou, Changye; Wu, Jun

doi:10.1039/d0bm01296c

Cited by 21 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug release experiments also proved that EM-Dox is more likely to release doxorubicin to kill osteosarcoma cells in the acidic environment of tumor lysosomes. Our results are similar to other drug delivery systems, with faster drug release in acidic environments (Li et al., 2020 ; Liu et al., 2021 ). In addition, similar to previous studies, the release of EM-Dox in physiological environments is lower than that of doxorubicin encapsulated in natural exosomes, demonstrating another advantage of EMs as a carrier (Goh et al., 2017 ; Wu et al., 2021 ).…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo

Wang

Jin

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

Osteosarcoma is a bone tumor with a high incidence in children and adolescents. Chemotherapy for osteosarcoma is limited, and effective targeted drugs are urgently needed to treat osteosarcoma. Exosomes as a natural nano drug delivery platform have been widely studied and proven to have good drug delivery performance. However, the low production of exosomes hinders its development as a carrier. Exosome mimetics (EMs) as an alternative product of exosomes solve the problem of low production of exosomes and maintain the good performance of exosomes as carriers. In this study, bone marrow mesenchymal stem cells (BMSCs) were sequentially extruded to generate EMs to encapsulate doxorubicin (EM-Dox) to treat osteosarcoma. The results showed that we successfully prepared EMs of BMSC, and EM-Dox was prepared using an active-loading approach. Our engineered EM-Dox demonstrated significantly more potent tumor inhibition activity and fewer side effects than free doxorubicin. This novel biological nanomedicine system provides a promising opportunity to develop novel precision medicine for osteosarcoma.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Li et al. ( 2020 ) treated advanced osteosarcoma with apatinib encapsulated by hydrophobic poly(ester amide) nanoparticles, significantly inhibiting tumor growth with very low side effects. Another study used polymeric nanoparticles to deliver NSC23766 to target the Rac1 pathway to improve prostate cancer treatment (Li et al., 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo

Wang

Jin

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…The deliveries of apatinib and cediranib using polymeric nanoparticles were tested for osteosarcoma and glioblastoma, respectively. Both of the studies showed synergistic results compared to individual drugs (56,57). Moreover, micelle nanoparticles were also studied in a study.…”

Section: Nanotechnology As the Potential Delivery Systemmentioning

confidence: 99%

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

et al. 2021

View full text Add to dashboard Cite

Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine kinase inhibitors for HCC therapy have been approved. The newly approved first-line drug donafenib represent the major milestones in HCC therapeutics in recent years. However, drug resistance in HCC remains challenging due to random mutations in target receptors as well as downstream pathways. TKIs-based combinatorial therapies with immune checkpoint inhibitors such as PD-1/PD-L1 antibodies afford a promising strategy to further clinical application. Recent developments of nanoparticle-based TKI delivery techniques improve drug absorption and bioavailability, enhance efficient targeting delivery, prolonged circulation time, and reduce harmful side effects on normal tissues, which may improve the therapeutic efficacy of the TKIs. In this review, we summarize the milestones and recent progress in clinical trials of TKIs for HCC therapy. We also provide an overview of the novel nanoparticle-based TKI delivery techniques that enable efficient therapy.

show abstract

“…It mainly occurs in children, adolescents, and young adults, the prognosis is very poor, and the survival rate is very low. 1,2 Surgical resection and chemotherapy can cure about 70% of patients. 3,4 However, there is still a lack of effective treatment for patients with advanced metastatic or recurrent osteosarcoma, which is due to tumor drug resistance.…”

Section: Introductionmentioning

confidence: 99%

“…The incidence rate of osteosarcoma is relatively high in primary malignant tumors. It mainly occurs in children, adolescents, and young adults, the prognosis is very poor, and the survival rate is very low. , Surgical resection and chemotherapy can cure about 70% of patients. , However, there is still a lack of effective treatment for patients with advanced metastatic or recurrent osteosarcoma, which is due to tumor drug resistance . Tumor immunotherapy, which regulates the body’s immunity through drugs or biological agents, can promote the phagocytosis of immune cells and eliminate drug-resistant tumor cells .…”

Section: Introductionmentioning

confidence: 99%

Macrophage Membrane-Coated Liposomes as Controlled Drug Release Nanocarriers for Precision Treatment of Osteosarcoma

Chen

et al. 2022

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Osteosarcoma has a relatively high incidence rate among primary malignant tumors, and the survival rate is low. Clinically, surgical resection and chemotherapy are mainly used, which are difficult to utilize to treat metastatic or recurrent osteosarcoma. The combination of chemotherapy and immunotherapy can achieve a better tumor treatment effect. M1 macrophages (M1 Mø) can kill tumor cells and have tumor-targeting and phagocytosis ability, which are an ideal tool for tumor-targeted drug delivery. However, as carriers, living cells have the disadvantages of uncontrollable size, poor tissue permeability, and poor stability. In this study, the M1 macrophage membrane (M1M) was used as the carrier and loaded with MMP-2 (matrix metalloproteinase-2)-sensitive drug-loaded liposomes (GL) to prepare a complex nanovesicle drug delivery system M1M (GL/DOX/TPI-1), with a tumor active targeting function, for combined chemical and immune therapy from doxorubicin (DOX) and tyrosine phosphatase inhibitor 1 (TPI-1). The complex nanovesicles not only retain the tumor-targeting ability from the M1 macrophage membrane but also have the advantages of controllable size, responsive drug release, and high stability. The results of in vivo efficacy test show that the drug delivery system realizes active targeted enrichment in osteosarcoma tissue. Under the response of MMP-2, the internally encapsulated antitumor drugs DOX and TPI-1 from the system are released. This drug delivery system combined with chemical and immune treatment can effectively achieve the aim of the treatment of osteosarcoma.

show abstract

Overcoming therapeutic failure in osteosarcomaviaApatinib-encapsulated hydrophobic poly(ester amide) nanoparticles

Abstract: Anti-angiogenesis tyrosine kinase inhibitors (TKIs) have been proved to be effective in prolonging progression-free survival in advanced osteosarcoma. However, osteosarcoma stem-like cells persist long term and ultimately cause disease recurrence...

Cited by 21 publications

References 43 publications

Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo

Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

Macrophage Membrane-Coated Liposomes as Controlled Drug Release Nanocarriers for Precision Treatment of Osteosarcoma

Contact Info

Product

Resources

About